In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Kamada (KMDA – Research Report), with a price target of $11.00.
Andrew Fein has given his Buy rating due to a combination of factors that highlight Kamada’s strong position for growth-oriented investors. The company has demonstrated impressive financial performance with record adjusted EBITDA and significant year-over-year sales growth, making it appealing to those seeking growth at a reasonable price. Kamada’s dual focus on its established plasma business and its innovative biotech pursuits, such as the inhaled AAT program, offers investors a balanced opportunity for stable revenue and potential upside.
Additionally, the company’s strategic moves, including a special dividend and plans for acquiring external commercial assets, suggest a prudent approach to expansion without deviating from its core operations. The straightforward catalyst calendar and expected positive developments in the acquisition of commercial assets further support the stock’s potential for appreciation. Moreover, the anticipated outcomes of the inhaled AAT program by the end of 2025 present multiple scenarios that could drive further stock value, making Kamada a compelling investment choice.